Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow

被引:23
作者
Pecci, A [1 ]
Travaglino, E [1 ]
Klersy, C [1 ]
Invernizzi, R [1 ]
机构
[1] Univ Pavia, IRCCS, Policlin San Matteo, I-27100 Pavia, Italy
关键词
apoptosis; CD34; antigen; myelodysplastic syndromes; stem cell;
D O I
10.1159/000067275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An increased bone marrow (BM) apoptosis is one of the mechanisms responsible for the ineffective hematopoiesis of myelodysplastic syndromes (MDS). It is controversial whether the excessive apoptosis in myelodysplasia predominantly involves the subset of progenitor cells or of maturing cells. We investigated the degree of apoptosis in MDS BM and its differences from normal marrow in relation to CD34 antigen expression. A double-labelling technique that combined the Tdt-mediated dUTP nick end labelling (TUNEL) method with immunocytochemistry for CD34 antigen was used on BM slides of 18 MDS patients and 11 controls. The apoptotic rate (AR) appeared significantly higher in CD34-negative than in CD34-positive cell subsets both in myelodysplastic and in normal BM. When MDS and normal CD34-negative cell populations were compared, a greater AR in MDS CD34-negative cells was found, while no statistical difference in AR resulted from the comparison between MDS and normal CD34-positive cell populations. Our results suggest that in myelodysplastic as well as in normal BM the apoptotic phenomenon predominantly involves the maturing cells. The increase in apoptotic levels which can be observed in myelodysplastic compared to normal BM seems to be mainly due to an increase in apoptosis in the differentiated cell population. Copyright (C) 2003 Karger AG, Basel.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 25 条
  • [1] [Anonymous], HEMATOLOGY BASIC PRI
  • [2] Aul C, 1998, HAEMATOLOGICA, V83, P71
  • [3] Berger G, 2001, Hematol J, V2, P87, DOI 10.1038/sj.thj.6200086
  • [4] Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes
    Bouscary, D
    DeVos, J
    Guesnu, M
    Jondeau, K
    Viguier, F
    Melle, J
    Picard, F
    Dreyfus, F
    FontenayRoupie, M
    [J]. LEUKEMIA, 1997, 11 (06) : 839 - 845
  • [5] Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment
    Greenberg, PL
    [J]. LEUKEMIA RESEARCH, 1998, 22 (12) : 1123 - 1136
  • [6] Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes
    Invernizzi, R
    Pecci, A
    Bellotti, L
    Ascari, E
    [J]. LEUKEMIA & LYMPHOMA, 2001, 42 (03) : 481 - 489
  • [7] Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia
    Kitagawa, M
    Yamaguchi, S
    Takahashi, M
    Tanizawa, T
    Hirokawa, K
    Kamiyama, R
    [J]. LEUKEMIA, 1998, 12 (04) : 486 - 492
  • [8] Koeffler HP, 1996, SEMIN HEMATOL, V33, P87
  • [9] THE BIOCHEMISTRY OF PROGRAMMED CELL-DEATH
    KROEMER, G
    PETIT, P
    ZAMZAMI, N
    VAYSSIERE, JL
    MIGNOTTE, B
    [J]. FASEB JOURNAL, 1995, 9 (13) : 1277 - 1287
  • [10] Is apoptosis a massive process in myelodysplastic syndromes?
    Lepelley, P
    Campergue, L
    Grardel, N
    Preudhomme, C
    Cosson, A
    Fenaux, P
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (02) : 368 - 371